EGFR and non-small cell lung carcinoma: However, other studies have reported differing results, indicating that further investigation is needed.177,178 Interestingly, another study involving patients with unresectable stage III NSCLC treated with chemoradiation followed by durvalumab consolidation revealed that KRAS-mutant lung cancers derived the greatest benefit from immunotherapy, reflected by their better PFS than did those with BRAF and EGFR mutations and ALK rearrangements.177